201 Haskins Way
South San Francisco, CA 94080
United States
650 695 0677
https://www.lyell.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 274
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Richard D. Klausner M.D. | Founder & Exec. Chairman | 80k | N/A | 1952 |
Dr. Lynn Seely M.D., Ph.D. | Pres, CEO & Director | 430.69k | N/A | 1959 |
Mr. Charles W. Newton | Chief Financial Officer | 1.72M | N/A | 1971 |
Mr. Stephen J. Hill | Chief Operating Officer | 1.04M | N/A | 1970 |
Dr. Gary Lee Ph.D. | Chief Scientific Officer | 639.91k | N/A | 1977 |
Ms. Elizabeth Homans | Consultant | 1.99M | N/A | 1966 |
Prof. Stanley R. Riddell M.D. | Founder & Scientific Advisor | N/A | N/A | N/A |
Dr. Crystal L. Mackall M.D. | Founder & Scientific Advisor | N/A | N/A | N/A |
Nellie Dillery | Director of Accounting | N/A | N/A | N/A |
Ms. Ellen Rose | Sr. VP of Communications & Investor Relations | N/A | N/A | N/A |
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, engages in developing T-cell reprogramming technologies for patients with solid tumors. It develops therapies using an ex vivo genetic reprogramming technologies, such as c-Jun overexpression and NR4A3 gene knockout, to endow resistance to T-cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi-R to generate population of T cells with durable stemness, and Stim-R, a proprietary synthetic cell mimetic. The company's pipeline includes LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T-cell product candidate for the treatment of various solid tumors; LYL845, an epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate that targets multiple solid tumors; LYL119, a CAR T-cell product candidate for enhanced cytotoxicity. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Lyell Immunopharma, Inc.’s ISS governance QualityScore as of 1 September 2023 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder rights: 8; Compensation: 9.